Corrigendum: Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review
Truong Van Dat, Vo Linh Tu, Le Nguyen Anh Thu, Nguyen Nhat Anh Quang, Van Binh, Nguyen Thi Quynh Nga, Duong Hoang Loc, Tran Thi Hong Nguyen, Dao Ngoc Hien Tam, Hong-Han Huynh, Tran Dinh Trung, Uyen Do, Nguyen Tuan Phat, Dang The Hung, Quang-Hien Nguyen, Nguyen Thi Hai Yen
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBlood Pressure and Hypertension Studies
In the published article, there was an error in Affiliation 1. Instead of “Department of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh city, Vietnam,” it should be “Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.”
In the published article, there was an error regarding the Affiliation for Tran Dinh Trung. Instead of “Department of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh city, Vietnam”, it should be “Faculty of Public Health, Danang University of Medical Technology and Pharmacy, Danang, Vietnam.”
In the published article, there was an error.
A correction has been made to Results, Main results, Safety, Paragraph Number 1. This paragraph previously stated:
“There were 14 studies that reported the safety of perindopril/amlodipine FDC (Supplementary Table S2). Of these, several serious but rare emergent adverse events (EAEs) of perindopril/amlodipine FDC have been reported, including stroke, brain infarction, cataracts, and diaphragmatic eventration (Hu et al., 2016). In the study by Fleig et al., eight patients (0.4%) experienced severe EAEs in 140 ADR of 88 patients, of which four patients (0.2%) did not recover and one patient died with a hypertensive crisis (Fleig et al., 2018).”
The corrected sentence appears below:
“There were 14 studies that reported the safety of perindopril/amlodipine FDC (Supplementary Table S2). Hu et al. reported emergent adverse events (EAEs) of perindopril/amlodipine FDC, including stroke (one patient), synovitis (one patient), pregnancy (one patient), cataracts (one patient), and diaphragmatic complications (one patient). While serious EAEs in the comparator drug group included lumbar intervertebral disc protrusion (one patient), cerebral infarction (one patient), and lacunar infarction (one patient) (Hu et al., 2016). In the study by Fleig et al., only eight patients (0.4%) experienced severe EAEs in 140 ADR of 88 patients, of which four patients (0.2%) did not recover and one patient died with a hypertensive crisis (Fleig et al., 2018).”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.